sub:provenance {
sub:_assertion prov:wasGeneratedBy "S&T TWOC Project - version 4" , "S&T TWOC version 3" .
sub:_version prov:value 2 .
sub:assertion prov:generatedAtTime "2023-07-20T09:47:22.930008"^^
xsd:dateTime ;
prov:wasAttributedTo orcid:0000-0003-4692-1377 ;
prov:wasDerivedFrom <
https://www.ncbi.nlm.nih.gov/pubmed/32827400/> .
rdf:OBJECT rdfs:label "antivirals like remdesivir , lopinavir , ritonavir , arbidol , oseltamivir , penciclovir , favipiravir , ganciclovir , and ribavirin ;" .
rdf:OBJECT-POSITION rdfs:label "(60, 66)" .
rdf:PREDICATE rdfs:label "including" .
rdf:PREDICATE-POSITION rdfs:label "67" .
rdf:SUBJECT rdfs:label "different pharmacological groups" .
rdf:SUBJECT-POSITION rdfs:label "(60, 66)" .
rdf:Statement rdfs:label "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." .
rdfs:ABSTRACT-UID ns2:50 "8j41d0a3" .
rdfs:TRIPLE-UID ns3:8j41d0a3-TRIPLE-ABSTRACT-1 "8j41d0a3-TRIPLE-ABSTRACT-1" .
<
https://uts.nlm.nih.gov/uts/umls/concept/C0687744>
rdfs:label "groups" .
<
https://uts.nlm.nih.gov/uts/umls/concept/C0874161>
rdfs:label "oseltamivir" .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA" ;
npx:hasPublicKey "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" ;
npx:hasSignature "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" ;
npx:hasSignatureTarget this: .
this: prov:wasAttributedTo orcid:0000-0003-4692-1377 .
}